Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameS-Adenosylmethionine
Accession NumberDB00118  (NUTR00052)
Typesmall molecule
Groupsapproved, nutraceutical
Description

Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)

Structure
Thumb
Synonyms
SynonymLanguageCode
AcylcarnitineNot AvailableNot Available
AdoMetNot AvailableNot Available
S-adenosyl-L-methionineNot AvailableNot Available
SAMNot AvailableNot Available
Salts
Name/CAS Structure Properties
S-Adenosylmethionine butanedisulfonate
Thumb Not applicable DBSALT000873
S-Adenosylmethionine disulfate ditosylate
Thumb Not applicable DBSALT000875
S-Adenosylmethionine disulfate monotosylate
Thumb Not applicable DBSALT000876
S-Adenosylmethionine disulfate tosylate
Thumb Not applicable DBSALT000874
S-Adenosylmethionine tosylate
Thumb Not applicable DBSALT000872
Brand names
NameCompany
Sam-SulfateNatrol
SAMeNot Available
SAMe Rx-MoodNature's Plus
Brand mixturesNot Available
CategoriesNot Available
CAS number29908-03-0
WeightAverage: 399.445
Monoisotopic: 399.145063566
Chemical FormulaC15H23N6O5S
InChI KeyInChIKey=MEFKEPWMEQBLKI-AIRLBKTGSA-O
InChI
InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/p+1/t7-,8+,10+,11+,14+,27?/m0/s1
IUPAC Name
[(3S)-3-amino-3-carboxypropyl]({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl})methylsulfanium
SMILES
C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(N)N=CN=C12
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassOrganooxygen Compounds
ClassCarbohydrates and Carbohydrate Conjugates
SubclassGlycosyl Compounds
Direct parentPurine Nucleosides and Analogues
Alternative parentsGlycoamino Acids and Derivatives; Pentoses; Alpha Amino Acids and Derivatives; Purines and Purine Derivatives; Amino Fatty Acids; Aminopyrimidines and Derivatives; Primary Aromatic Amines; N-substituted Imidazoles; Oxolanes; Tetrahydrofurans; Secondary Alcohols; 1,2-Diols; Carboxylic Acids; Enolates; Polyamines; Ethers; Monoalkylamines
Substituentsalpha-amino acid or derivative; pentose monosaccharide; purine; imidazopyrimidine; aminopyrimidine; pyrimidine; primary aromatic amine; monosaccharide; n-substituted imidazole; tetrahydrofuran; oxolane; imidazole; azole; secondary alcohol; 1,2-diol; carboxylic acid derivative; polyamine; carboxylic acid; enolate; ether; primary amine; primary aliphatic amine; alcohol; organonitrogen compound; amine
Classification descriptionThis compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.
Pharmacology
IndicationS-Adenosylmethionine (SAMe) is used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. It has also been introduced into the United States market as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being.
PharmacodynamicsS-adenosylmethionine is an intermediate metabolite of methionine. Its involvement in methylation assists in cellular growth and repair, maintains the phospho-bilipid layer in cell membranes. It also helps in the maintenance of the action of several hormones and neurotransmitters that affect mood. Highest concentration are found in the brain and the liver.
Mechanism of actionS-Adenosylmethionine (SAMe) is a natural substance present in the cells of the body. It is a direct metabolite of the essential amino acid L-methionine. SAMe plays a crucial biochemical role in the body by donating a one-carbon methyl group in a process called transmethylation. SAMe, formed from the reaction of L-methionine and adenosine triphosphate catalyzed by the enzyme S-adenosylmethionine synthetase, is the methyl-group donor in the biosynthesis of both DNA and RNA nucleic acids, phospholipids, proteins, epinephrine, melatonin, creatine and other molecules.
AbsorptionS-Adenosylmethionine is absorbed from the small intestine following oral intake. As absorption is affected by food, it is best to take on an empty stomach. Bioavailability is low following oral intake.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Significant first-pass metabolism in the liver. Approximately 50% of S-Adenosylmethionine (SAMe) is metabolized in the liver. SAMe is metabolized to S-adenosylhomocysteine, which is then metabolized to homocysteine. Homocysteine can either be metabolized to cystathionine and then cysteine or to methionine. The cofactor in the metabolism of homocysteine to cysteine is vitamin B6. Cofactors for the metabolism of homocysteine to methionine are folic acid, vitamin B12 and betaine.

SubstrateEnzymesProduct
S-Adenosylmethionine
    CystathionineDetails
    S-Adenosylmethionine
      CysteineDetails
      S-Adenosylmethionine
        MethionineDetails
        S-Adenosylmethionine
          HomocysteineDetails
          S-Adenosylmethionine
            S-AdenosylhomocysteineDetails
            Route of eliminationNot Available
            Half lifeNot Available
            ClearanceNot Available
            ToxicityIrritating to mucus membranes and upper respiratory tract. Can cause CNS depression.
            Affected organisms
            • Humans and other mammals
            Pathways
            PathwayCategorySMPDB ID
            Thioguanine Action PathwayDrug actionSMP00430
            Azathioprine Action PathwayDrug actionSMP00427
            Mercaptopurine Action PathwayDrug actionSMP00428
            Phenytoin (Antiarrhythmic) Action PathwayDrug actionSMP00327
            Disulfiram Action PathwayDrug actionSMP00429
            S-Adenosylhomocysteine (SAH) Hydrolase DeficiencyDiseaseSMP00214
            Methionine Adenosyltransferase DeficiencyDiseaseSMP00221
            Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)DiseaseSMP00362
            AlkaptonuriaDiseaseSMP00169
            L-arginine:glycine amidinotransferase deficiencyDiseaseSMP00507
            Aromatic L-Aminoacid Decarboxylase DeficiencyDiseaseSMP00170
            Ornithine Aminotransferase Deficiency (OAT Deficiency)DiseaseSMP00363
            Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism, cblG complementation typeDiseaseSMP00570
            Arginine and Proline MetabolismMetabolicSMP00020
            Hyperornithinemia with gyrate atrophy (HOGA)DiseaseSMP00505
            Cystathionine Beta-Synthase DeficiencyDiseaseSMP00177
            Dopamine beta-hydroxylase deficiencyDiseaseSMP00498
            Betaine MetabolismMetabolicSMP00123
            Spermidine and Spermine BiosynthesisMetabolicSMP00445
            Ubiquinone BiosynthesisMetabolicSMP00065
            Catecholamine BiosynthesisMetabolicSMP00012
            Carnitine SynthesisMetabolicSMP00465
            Creatine deficiency, guanidinoacetate methyltransferase deficiencyDiseaseSMP00504
            Prolidase Deficiency (PD)DiseaseSMP00207
            Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)DiseaseSMP00188
            Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)DiseaseSMP00340
            Glycine N-methyltransferase DeficiencyDiseaseSMP00222
            Dimethylglycine Dehydrogenase DeficiencyDiseaseSMP00242
            Dihydropyrimidine Dehydrogenase Deficiency (DHPD)DiseaseSMP00179
            Monoamine oxidase-a deficiency (MAO-A)DiseaseSMP00533
            Tyrosine hydroxylase deficiencyDiseaseSMP00497
            DimethylglycinuriaDiseaseSMP00484
            Glycine and Serine MetabolismMetabolicSMP00004
            HawkinsinuriaDiseaseSMP00190
            Hyperornithinemia-hyperammonemia-homocitrullinuria [HHH-syndrome]DiseaseSMP00506
            Histidine MetabolismMetabolicSMP00044
            HistidinemiaDiseaseSMP00191
            Non Ketotic HyperglycinemiaDiseaseSMP00223
            Hyperglycinemia, non-ketoticDiseaseSMP00485
            HypermethioninemiaDiseaseSMP00341
            Hyperprolinemia Type IIDiseaseSMP00360
            Hyperprolinemia Type IDiseaseSMP00361
            Tyrosinemia Type IDiseaseSMP00218
            Prolinemia Type IIDiseaseSMP00208
            Mercaptopurine Metabolism PathwayDrug metabolismSMP00609
            Nicotinate and Nicotinamide MetabolismMetabolicSMP00048
            Tyrosine MetabolismMetabolicSMP00006
            Tryptophan MetabolismMetabolicSMP00063
            Methionine MetabolismMetabolicSMP00033
            Tyrosinemia, transient, of the newbornDiseaseSMP00494
            SarcosinemiaDiseaseSMP00244
            SNP Mediated EffectsNot Available
            SNP Mediated Adverse Drug ReactionsNot Available
            ADMET
            Predicted ADMET features
            Property Value Probability
            Human Intestinal Absorption + 0.8102
            Blood Brain Barrier - 0.8894
            Caco-2 permeable - 0.7307
            P-glycoprotein substrate Substrate 0.7584
            P-glycoprotein inhibitor I Non-inhibitor 0.9664
            P-glycoprotein inhibitor II Non-inhibitor 0.993
            Renal organic cation transporter Non-inhibitor 0.9295
            CYP450 2C9 substrate Non-substrate 0.8308
            CYP450 2D6 substrate Non-substrate 0.8224
            CYP450 3A4 substrate Substrate 0.5753
            CYP450 1A2 substrate Non-inhibitor 0.8308
            CYP450 2C9 substrate Non-inhibitor 0.8396
            CYP450 2D6 substrate Non-inhibitor 0.9192
            CYP450 2C19 substrate Non-inhibitor 0.8457
            CYP450 3A4 substrate Non-inhibitor 0.9731
            CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9647
            Ames test Non AMES toxic 0.6899
            Carcinogenicity Non-carcinogens 0.9417
            Biodegradation Not ready biodegradable 0.9486
            Rat acute toxicity 2.5758 LD50, mol/kg Not applicable
            hERG inhibition (predictor I) Weak inhibitor 0.9755
            hERG inhibition (predictor II) Non-inhibitor 0.7962
            Pharmacoeconomics
            ManufacturersNot Available
            Packagers
            Dosage forms
            FormRouteStrength
            CapsuleOral100 mg
            CapsuleOral200 mg
            CapsuleOral50 mg
            Capsule, delayed releaseOral200 mg
            TabletOral100 mg
            TabletOral200 mg
            Prices
            Unit descriptionCostUnit
            Sam-e 400 mg tablet0.86USDtablet
            CVS Pharmacy sam-e 400 mg tablet0.79USDtablet
            Sam-e 200 mg tablet0.59USDtablet
            DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
            PatentsNot Available
            Properties
            Statesolid
            Experimental Properties
            PropertyValueSource
            boiling point78 °CNot Available
            Predicted Properties
            PropertyValueSource
            water solubility1.19e+00 g/lALOGPS
            logP-2ALOGPS
            logP-5.3ChemAxon
            logS-2.6ALOGPS
            pKa (strongest acidic)1.71ChemAxon
            pKa (strongest basic)9.41ChemAxon
            physiological charge1ChemAxon
            hydrogen acceptor count10ChemAxon
            hydrogen donor count5ChemAxon
            polar surface area182.63ChemAxon
            rotatable bond count7ChemAxon
            refractivity96.23ChemAxon
            polarizability40.37ChemAxon
            number of rings3ChemAxon
            bioavailability1ChemAxon
            rule of fiveYesChemAxon
            Ghose filterNoChemAxon
            Veber's ruleNoChemAxon
            MDDR-like ruleYesChemAxon
            Spectra
            SpectraNot Available
            References
            Synthesis Reference

            Takayasu Tsuchida, Fumihiro Yoshinaga, Shinji Okumura, “Method for producing S-adenosylmethionine or methylthioadenosine by yeast.” U.S. Patent US3962034, issued November, 1971.

            US3962034
            General Reference
            1. Finkelstein JD, Martin JJ: Homocysteine. Int J Biochem Cell Biol. 2000 Apr;32(4):385-9. Pubmed
            2. Fodinger M, Horl WH, Sunder-Plassmann G: Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol. 2000 Jan-Feb;13(1):20-33. Pubmed
            3. Roje S: S-Adenosyl-L-methionine: beyond the universal methyl group donor. Phytochemistry. 2006 Aug;67(15):1686-98. Pubmed
            4. Loenen WA: S-adenosylmethionine: jack of all trades and master of everything? Biochem Soc Trans. 2006 Apr;34(Pt 2):330-3. Pubmed
            5. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP: S-Adenosylmethionine and methylation. FASEB J. 1996 Mar;10(4):471-80. Pubmed
            External Links
            ResourceLink
            KEGG CompoundC00019
            PubChem Compound34756
            PubChem Substance46505280
            ChemSpider31983
            ChEBI15414
            ChEMBLCHEMBL1088977
            PharmGKBPA164754994
            HETSAM
            Drugs.comhttp://www.drugs.com/cdi/s-adenosylmethionine.html
            PDRhealthhttp://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/sad_0231.shtml
            WikipediaS-Adenosylmethionine
            ATC CodesNot Available
            AHFS CodesNot Available
            PDB Entries
            FDA labelNot Available
            MSDSshow(35.5 KB)
            Interactions
            Drug Interactions
            Drug
            DesvenlafaxineIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
            Ginkgo bilobaAdditive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
            KetoprofenIncreased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
            SulindacS-adenosylmethionine may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided.
            TramadolIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
            TranylcypromineIncreased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
            TrazodoneIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
            TrimipramineIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
            VenlafaxineIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
            WarfarinAdditive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided.
            ZolmitriptanUse of two serotonin modulators, such as zolmitriptan and S-adenosylmethionine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
            Food InteractionsNot Available

            1. Glycine N-methyltransferase

            Kind: protein

            Organism: Human

            Pharmacological action: unknown

            Actions: cofactor

            Components

            Name UniProt ID Details
            Glycine N-methyltransferase Q14749 Details

            References:

            1. Rowling MJ, Schalinske KL: Retinoid compounds activate and induce hepatic glycine N-methyltransferase in rats. J Nutr. 2001 Jul;131(7):1914-7. Pubmed
            2. Luka Z, Cerone R, Phillips JA 3rd, Mudd HS, Wagner C: Mutations in human glycine N-methyltransferase give insights into its role in methionine metabolism. Hum Genet. 2002 Jan;110(1):68-74. Epub 2001 Dec 7. Pubmed
            3. Rowling MJ, McMullen MH, Chipman DC, Schalinske KL: Hepatic glycine N-methyltransferase is up-regulated by excess dietary methionine in rats. J Nutr. 2002 Sep;132(9):2545-50. Pubmed
            4. Moller MT, Samari HR, Fengsrud M, Stromhaug PE, oStvold AC, Seglen PO: Okadaic acid-induced, naringin-sensitive phosphorylation of glycine N-methyltransferase in isolated rat hepatocytes. Biochem J. 2003 Jul 15;373(Pt 2):505-13. Pubmed
            5. Uthus EO, Brown-Borg HM: Altered methionine metabolism in long living Ames dwarf mice. Exp Gerontol. 2003 May;38(5):491-8. Pubmed

            2. S-adenosylmethionine decarboxylase proenzyme

            Kind: protein

            Organism: Human

            Pharmacological action: unknown

            Actions: cofactor

            Components

            Name UniProt ID Details
            S-adenosylmethionine decarboxylase proenzyme P17707 Details

            References:

            1. Dudkowska M, Stachurska A, Grzelakowska-Sztabert B, Manteuffel-Cymborowska M: Up-regulation of spermidine/spermine N1-acetyltransferase (SSAT) expression is a part of proliferative but not anabolic response of mouse kidney. Acta Biochim Pol. 2002;49(4):969-77. Pubmed
            2. Ndjonka D, Zou Y, Bi X, Woster P, Walter RD, Luersen K: The activator-binding site of Onchocerca volvulus S-adenosylmethionine decarboxylase, a potential drug target. Biol Chem. 2003 Aug;384(8):1195-201. Pubmed
            3. Notari S, Lucchi R, Traversa U, Fabbri E, Poli A: Reversible changes in goldfish brain polyamine concentrations and synthetic enzymes after cold exposure. Brain Res. 2004 May 1;1006(2):241-7. Pubmed
            4. Yerlikaya A, Stanley BA: Structural basis for the inactivation of AdoMetDC K12R mutant. Protein Pept Lett. 2006;13(3):313-7. Pubmed

            3. S-adenosylmethionine synthase isoform type-2

            Kind: protein

            Organism: Human

            Pharmacological action: unknown

            Actions: cofactor

            Components

            Name UniProt ID Details
            S-adenosylmethionine synthase isoform type-2 P31153 Details

            References:

            1. Mudd SH, Cerone R, Schiaffino MC, Fantasia AR, Minniti G, Caruso U, Lorini R, Watkins D, Matiaszuk N, Rosenblatt DS, Schwahn B, Rozen R, LeGros L, Kotb M, Capdevila A, Luka Z, Finkelstein JD, Tangerman A, Stabler SP, Allen RH, Wagner C: Glycine N-methyltransferase deficiency: a novel inborn error causing persistent isolated hypermethioninaemia. J Inherit Metab Dis. 2001 Aug;24(4):448-64. Pubmed
            2. Farrar C, Clarke S: Altered levels of S-adenosylmethionine and S-adenosylhomocysteine in the brains of L-isoaspartyl (D-Aspartyl) O-methyltransferase-deficient mice. J Biol Chem. 2002 Aug 2;277(31):27856-63. Epub 2002 May 22. Pubmed
            3. Martinez-Chantar ML, Latasa MU, Varela-Rey M, Lu SC, Garcia-Trevijano ER, Mato JM, Avila MA: L-methionine availability regulates expression of the methionine adenosyltransferase 2A gene in human hepatocarcinoma cells: role of S-adenosylmethionine. J Biol Chem. 2003 May 30;278(22):19885-90. Epub 2003 Mar 26. Pubmed
            4. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, Martin-Duce A, Fortes P, Caballeria J, Avila MA, Mato JM: Methionine adenosyltransferase II beta subunit gene expression provides a proliferative advantage in human hepatoma. Gastroenterology. 2003 Apr;124(4):940-8. Pubmed

            4. Cystathionine beta-synthase

            Kind: protein

            Organism: Human

            Pharmacological action: unknown

            Actions: activator

            Components

            Name UniProt ID Details
            Cystathionine beta-synthase P35520 Details

            References:

            1. Janosik M, Kery V, Gaustadnes M, Maclean KN, Kraus JP: Regulation of human cystathionine beta-synthase by S-adenosyl-L-methionine: evidence for two catalytically active conformations involving an autoinhibitory domain in the C-terminal region. Biochemistry. 2001 Sep 4;40(35):10625-33. Pubmed
            2. Jacobs RL, Stead LM, Brosnan ME, Brosnan JT: Hyperglucagonemia in rats results in decreased plasma homocysteine and increased flux through the transsulfuration pathway in liver. J Biol Chem. 2001 Nov 23;276(47):43740-7. Epub 2001 Sep 14. Pubmed
            3. Choumenkovitch SF, Selhub J, Bagley PJ, Maeda N, Nadeau MR, Smith DE, Choi SW: In the cystathionine beta-synthase knockout mouse, elevations in total plasma homocysteine increase tissue S-adenosylhomocysteine, but responses of S-adenosylmethionine and DNA methylation are tissue specific. J Nutr. 2002 Aug;132(8):2157-60. Pubmed
            4. Evande R, Blom H, Boers GH, Banerjee R: Alleviation of intrasteric inhibition by the pathogenic activation domain mutation, D444N, in human cystathionine beta-synthase. Biochemistry. 2002 Oct 1;41(39):11832-7. Pubmed

            5. S-adenosylmethionine synthase isoform type-1

            Kind: protein

            Organism: Human

            Pharmacological action: unknown

            Actions: cofactor

            Components

            Name UniProt ID Details
            S-adenosylmethionine synthase isoform type-1 Q00266 Details

            References:

            1. Carretero MV, Latasa MU, Garcia-Trevijano ER, Corrales FJ, Wagner C, Mato JM, Avila MA: Inhibition of liver methionine adenosyltransferase gene expression by 3-methylcolanthrene: protective effect of S-adenosylmethionine. Biochem Pharmacol. 2001 May 1;61(9):1119-28. Pubmed
            2. Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA, Garcia-Trevijano ER, Huang ZZ, Chen L, Kanel G, Avila MA, Mato JM, Lu SC: Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 2002 Aug;16(10):1292-4. Epub 2002 Jun 7. Pubmed
            3. Santamaria E, Avila MA, Latasa MU, Rubio A, Martin-Duce A, Lu SC, Mato JM, Corrales FJ: Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3065-70. Epub 2003 Mar 11. Pubmed
            4. Martinez-Chantar ML, Latasa MU, Varela-Rey M, Lu SC, Garcia-Trevijano ER, Mato JM, Avila MA: L-methionine availability regulates expression of the methionine adenosyltransferase 2A gene in human hepatocarcinoma cells: role of S-adenosylmethionine. J Biol Chem. 2003 May 30;278(22):19885-90. Epub 2003 Mar 26. Pubmed
            5. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, Martin-Duce A, Fortes P, Caballeria J, Avila MA, Mato JM: Methionine adenosyltransferase II beta subunit gene expression provides a proliferative advantage in human hepatoma. Gastroenterology. 2003 Apr;124(4):940-8. Pubmed

            6. Catechol O-methyltransferase

            Kind: protein

            Organism: Human

            Pharmacological action: unknown

            Actions: cofactor

            Components

            Name UniProt ID Details
            Catechol O-methyltransferase P21964 Details

            References:

            1. Lee BW, Sun HG, Zang T, Kim BJ, Alfaro JF, Zhou ZS: Enzyme-catalyzed transfer of a ketone group from an S-adenosylmethionine analogue: a tool for the functional analysis of methyltransferases. J Am Chem Soc. 2010 Mar 24;132(11):3642-3. Pubmed
            2. Rutherford K, Le Trong I, Stenkamp RE, Parson WW: Crystal structures of human 108V and 108M catechol O-methyltransferase. J Mol Biol. 2008 Jun 27;380(1):120-30. Epub 2008 Apr 23. Pubmed

            1. Cytochrome P450 2E1

            Kind: protein

            Organism: Human

            Pharmacological action: unknown

            Actions: inhibitor

            Components

            Name UniProt ID Details
            Cytochrome P450 2E1 P05181 Details

            References:

            1. Caro AA, Cederbaum AI: Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93. Pubmed
            2. Cederbaum AI: Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. World J Gastroenterol. 2010 Mar 21;16(11):1366-76. Pubmed

            2. Spermidine synthase

            Kind: protein

            Organism: Human

            Pharmacological action: unknown

            Actions: substrate

            Components

            Name UniProt ID Details
            Spermidine synthase P19623 Details

            References:

            1. Cyriac J, Haleem R, Cai X, Wang Z: Androgen regulation of spermidine synthase expression in the rat prostate. Prostate. 2002 Mar 1;50(4):252-61. Pubmed
            2. Dejima H, Kobayashi M, Takasaki H, Takeda N, Shirahata A, Samejima K: Synthetic decarboxylated S-adenosyl-L-methionine as a substrate for aminopropyl transferases. Biol Pharm Bull. 2003 Jul;26(7):1005-8. Pubmed
            3. Franceschetti M, Fornale S, Tassonia A, Zuccherelli K, Mayer MJ, Bagni N: Effects of spermidine synthase overexpression on polyamine biosynthetic pathway in tobacco plants. J Plant Physiol. 2004 Sep;161(9):989-1001. Pubmed

            Comments
            Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:08